1.Disseminated histoplasmosis in a 53-year-old HIV-negative Filipino male: A case report
Dana Andrea D. Nery, MD ; Maria Katherina Lat-Herrin, MD, FPDS, FDSP-PDS ; Mary Elizabeth Danga, MD, FPDS, FDSP-PDS
Journal of the Philippine Dermatological Society 2023;32(1):47-52
Introduction:
Histoplasmosis is a disease of global distribution with diverse manifestations caused by the dimorphic fungus Histoplasma capsulatum. It is frequently described in severely immunocompromised and Human Immunodeficiency Virus (HIV)-positive
individuals. Despite being widely reported in Southeast Asia, few cases have been reported in the Philippines.
Case Report:
A 53-year-old Filipino male who presented with umbilicated papules resembling molluscum contagiosum, and a previous
history of a left lung mass with initial complaints of cough and hemoptysis. Gram stain of his sputum revealed the presence of fungal
elements, otherwise not specified. In relation to this, a fine-needle aspiration biopsy of the suspected lung mass was done. However,
findings were negative for malignant cells and fungi.
Dermoscopy revealed central ulceration and necrosis with faint peripheral arborizing telangiectasia and surrounding superficial scaling.
Histopathologic analysis revealed a diffuse granulomatous dermatitis, and Periodic acid-Schiff (PAS) and Grocott methenamine silver
(GMS) stains showed numerous small yeast-like structures measuring approximately 3.74µm in diameter. Tissue culture of the skin lesion
on the right thigh isolated fungal elements but was not specified. As histoplasmosis is an AIDS-defining infection and often found in immunocompromised states, screening for HIV was done which revealed negative results. Interestingly, disease distribution of histoplasmosis in the Philippines was frequently found in HIV-negative patients. Due to persistent serum creatinine elevation of over 300 µmol/L,
renal biopsy was also done and revealed similar fungal elements. With these findings, a diagnosis of disseminated histoplasmosis was
made. After a month of treatment with oral itraconazole, there was marked improvement of the patient’s skin lesions.
Conclusion
This case highlights the importance of recognizing cutaneous manifestations and maintaining a high index of suspicion for
histoplasmosis in HIV-seronegative patients.
systemic fungal infections
;
disseminated histoplasmosis
;
itraconazole
2.A rare case of disseminated Histoplasmosis mimicking Varicella in a 28-year-old immunocompetent female.
Sheehan Mae A. Tolentino ; Jacqueline Michelle D. Melendres ; Francisco Rivera IV ; Maicka Kiersten O. Agon ; Miyahra Haniko Lopez
Journal of the Philippine Medical Association 2023;101(2):33-38
Histoplasmosis is well-characterized as a fungal
disease that more commonly occurs in North America,
mostly endemic in Ohio and Mississippi river valleys.
The clinical spectrum of histoplasmosis ranges from
asymptomatic infection to a fatal disease. Progressive
disseminated histoplasmosis is typically seen in
immunocompromised individuals and presents with
non-specific systemic symptoms associated with
cutaneous manifestations of papules and nodules.? We
report a case of a 28-year old Filipino female with a
history of exposure to soil activities months before
consult. The patient presented with a 3-week history of
erythematous macules, vesicles, and pustules over the
face, arms, and trunk, which evolve into papules and
plaques with hemorrhagic crusting. Patient was initially
diagnosed and treated as a case of varicella but had no
improvement with initial management. Histopathologic
findings were consistent with histoplasmosis. The
patient was started with oral itraconazole, but
unexpectedly expired before any improvement in
cutaneous symptoms were noted.
Disseminated histoplasmosis
;
Itraconazole
3.Antifungal susceptibility of clinically isolated invasive Candida tropicalis in East China from 2017 to 2021.
Fei Fei WAN ; Min ZHANG ; Jian GUO ; Wen Juan WU
Chinese Journal of Preventive Medicine 2023;57(10):1542-1549
Objective: To explore the epidemiological characteristics of sample distribution and antifungal susceptibilities of clinically invasive C. tropicalis isolates from 2017 to 2021 in East China. Methods: Using a retrospective analysis, the East China Invasive Fungal Infection Group (ECIFIG) collected C. tropicalis clinically isolated from 32 hospitals in East China between January 2017 and December 2021. The identification results of the strains were reviewed using mass spectrometry by the central laboratory of the Shanghai East Hospital. The minimum inhibitory concentrations (MICs) of the strains against fluconazole (FLU), voriconazole (VOR), itraconazole (ITR), Posaconazole (POS), isavuconazole (ISA), anidulafungin (ANI), caspofungin (CAS), micafungin (MICA) and 5-fluorocytosine (FCT) were tested by the ThermoFisher CMC1JHY colorimetric microdilution method. The MIC of amphotericin B (AMB) was tested by the broth microdilution method. The MIC results were analyzed based on the clinical breakpoints and epidemiological cutoff values (ECV) published by the Clinical and Laboratory Standards Institute (CLSI) M27 Ed3 and M57 Ed4 documents. Data analysis was conducted using the Kruskal-Wallis test and paired t-test. Results: In total, 305 C. tropicalis isolates were collected. There were 38.0% (116/305) strains isolated from blood, 11.5% (35/305) ascites, 8.9% (27/305) catheter and 8.9% (27/305) drainage fluid. The resistance rate of C. tropicalis to FLU was 32.5%, to VOR was 28.5%, and the cross-resistance rate to FLU and VOR was 28.5%. The wild-type proportions for ITR and POS were 79.3% and 29.2% respectively. There was no significant difference in resistance rates, MIC50, and MIC90 of FLU and VOR, or in the wild-type rates of ITR and POS over five years. More than 95.0% of the isolates were susceptible to echinocandins. However, one strain was identified as being multi-drug resistant. In azole antifungals, voriconazole, itraconazole, posaconazole, and isavuconazole have similar GM MIC values. The GM MIC of fluconazole is significantly higher than that of itraconazole (t=9.95, P<0.05), posaconazole (t=9.99, P<0.05), and voriconazole (t=10.01, P<0.05), Meanwhile, among echinocandins, the GM MIC of ANI was comparable to that of CAS (t=1.17, P>0.05), both of which were significantly higher than MICA (t=11.56, P<0.05; t=4.15, P<0.05). Conclusion: The clinical isolates of C. tropicalis in East China from 2017 to 2021 were relatively susceptible to echinocandins. However, there was consistently high resistance to fluconazole and voriconazole. More intensive efforts should be made on the monitoring of drug resistance in C. tropicalis.
Humans
;
Antifungal Agents/pharmacology*
;
Fluconazole/pharmacology*
;
Candida tropicalis
;
Voriconazole/pharmacology*
;
Itraconazole/pharmacology*
;
Retrospective Studies
;
Candida
;
China/epidemiology*
;
Echinocandins/pharmacology*
;
Microbial Sensitivity Tests
4.Antifungal susceptibility of clinically isolated invasive Candida tropicalis in East China from 2017 to 2021.
Fei Fei WAN ; Min ZHANG ; Jian GUO ; Wen Juan WU
Chinese Journal of Preventive Medicine 2023;57(10):1542-1549
Objective: To explore the epidemiological characteristics of sample distribution and antifungal susceptibilities of clinically invasive C. tropicalis isolates from 2017 to 2021 in East China. Methods: Using a retrospective analysis, the East China Invasive Fungal Infection Group (ECIFIG) collected C. tropicalis clinically isolated from 32 hospitals in East China between January 2017 and December 2021. The identification results of the strains were reviewed using mass spectrometry by the central laboratory of the Shanghai East Hospital. The minimum inhibitory concentrations (MICs) of the strains against fluconazole (FLU), voriconazole (VOR), itraconazole (ITR), Posaconazole (POS), isavuconazole (ISA), anidulafungin (ANI), caspofungin (CAS), micafungin (MICA) and 5-fluorocytosine (FCT) were tested by the ThermoFisher CMC1JHY colorimetric microdilution method. The MIC of amphotericin B (AMB) was tested by the broth microdilution method. The MIC results were analyzed based on the clinical breakpoints and epidemiological cutoff values (ECV) published by the Clinical and Laboratory Standards Institute (CLSI) M27 Ed3 and M57 Ed4 documents. Data analysis was conducted using the Kruskal-Wallis test and paired t-test. Results: In total, 305 C. tropicalis isolates were collected. There were 38.0% (116/305) strains isolated from blood, 11.5% (35/305) ascites, 8.9% (27/305) catheter and 8.9% (27/305) drainage fluid. The resistance rate of C. tropicalis to FLU was 32.5%, to VOR was 28.5%, and the cross-resistance rate to FLU and VOR was 28.5%. The wild-type proportions for ITR and POS were 79.3% and 29.2% respectively. There was no significant difference in resistance rates, MIC50, and MIC90 of FLU and VOR, or in the wild-type rates of ITR and POS over five years. More than 95.0% of the isolates were susceptible to echinocandins. However, one strain was identified as being multi-drug resistant. In azole antifungals, voriconazole, itraconazole, posaconazole, and isavuconazole have similar GM MIC values. The GM MIC of fluconazole is significantly higher than that of itraconazole (t=9.95, P<0.05), posaconazole (t=9.99, P<0.05), and voriconazole (t=10.01, P<0.05), Meanwhile, among echinocandins, the GM MIC of ANI was comparable to that of CAS (t=1.17, P>0.05), both of which were significantly higher than MICA (t=11.56, P<0.05; t=4.15, P<0.05). Conclusion: The clinical isolates of C. tropicalis in East China from 2017 to 2021 were relatively susceptible to echinocandins. However, there was consistently high resistance to fluconazole and voriconazole. More intensive efforts should be made on the monitoring of drug resistance in C. tropicalis.
Humans
;
Antifungal Agents/pharmacology*
;
Fluconazole/pharmacology*
;
Candida tropicalis
;
Voriconazole/pharmacology*
;
Itraconazole/pharmacology*
;
Retrospective Studies
;
Candida
;
China/epidemiology*
;
Echinocandins/pharmacology*
;
Microbial Sensitivity Tests
5.Clinical analysis of 7 children infected with Talaromyces marneffei.
Gan XIE ; Jie Hua CHEN ; Li Fang SUN ; Wei WANG ; Zhi Chuan LI ; Wen Jian WANG
Chinese Journal of Pediatrics 2022;60(9):925-929
Objective: To investigate the clinical manifestations, treatments, and prognosis of pediatric patients with Talaromyces marneffei infection. Methods: In this retrospective study, 7 children diagnosed with Talaromyces marneffei infection in Shenzhen Children's Hospital from July 2017 to October 2021 were recruited. The clinical features, radiology, pathogen detection, immunological evaluation, treatments, and prognosis were analyzed. Results: In 7 cases, 5 were male, 2 were females. The age was from 0.75 to 8.75 years. The main clinical manifestations were fever in 7 cases, cough in 6 cases, malnutrition in 4 cases, papules in 2 cases and medical history of recurrent infection in 3 cases. Physical examination showed that all 7 patients had hepatosplenomegaly, 4 had superficial lymphadenopathy. Laboratory examination showed that 6 cases had decreased hemoglobin and 3 cases had decreased platelet. Chest CT showed that 4 cases had patchy shadows, pleural effusion, mediastinal or axillary lymph node enlargement, 3 had nodular shadows and 2 had cavities. The positive ratio of Talaromyces marneffei culture was 2/2 with tissue samples, 4/5 with bone marrow. The positive ratio was 3/4 by metagenomic next generation sequencing. The fungus was detected in 3 cases by smear microscopy of bone marrow and (or) peripheral blood. All patients were negative for human immunodeficiency virus by the immune function assay. However, 5 cases were confirmed as primary immunodeficiency disease, including 2 cases with high IgM syndrome, 2 with STAT1 gene variation, and the last with severe combined immunodeficiency (IL2RG gene variation). Exclude 1 case which gave up treatment due to acute intracranial infection, and the other patients received effective treatments along with amphotericin B, voriconazole, and itraconazole alone or in combination. Two cases relapsed after medication withdrawal, but 1 case got complete rehabilitation after hematopoietic stem cell transplantation. Conclusions: The clinical manifestations involve multisystem, the common charateristics are fever and cough. The chest CT imaging manifestations are diverse, it should be considered in differentiating tuberculosis. The amphotericin B, voriconazole and itraconazole are effective, but it will easily relapse when withdrawing those antifungal agents.
Amphotericin B/therapeutic use*
;
Antifungal Agents/therapeutic use*
;
Child
;
Child, Preschool
;
Cough
;
Female
;
Fever
;
Humans
;
Infant
;
Itraconazole/therapeutic use*
;
Male
;
Mycoses
;
Retrospective Studies
;
Talaromyces
;
Voriconazole
6.Effects of Arsenic Disulfide Combined with Itraconazole on Proli- feration and Apoptosis and Hedgehog Pathway of Diffuse Large B-Cell Lymphoma Cells.
Ling WANG ; Shi-Quan DING ; Hua-Wei LI ; Sheng-Hong DU ; Chen CHEN ; Yu-Yu LIU ; Ban-Ban LI ; Cong LIU ; Jun JIAO ; Qing-Liang TENG
Journal of Experimental Hematology 2021;29(5):1504-1509
OBJECTIVE:
To investigate the effect of arsenic disulfide (AS
METHODS:
The human DLBCL cell OCI-LY3 was treated with different concentrations of AS
RESULTS:
The DLBCL cell viability was decreased significantly at 24, 48 or 72 h as cultured with itraconazole. Along with the increasing of itraconazole concentration, the DLBCL cell viability was significantly reduced as compared with that in control group, and the results showed statistically significant(r=-0.690,r=-0.639, r=-0.833, r=-0.808, r=-0.578). The inhibitory and apoptosis rates of the cells were significantly increased as compared with those of the single drug-treated group after treated by the combination of itraconazole and AS
CONCLUSION
Itraconazole can inhibit proliferation of DLBCL cells in a concentration-and time-dependent manner. In addition, the combination of AS
Apoptosis
;
Arsenicals
;
Hedgehog Proteins
;
Humans
;
Itraconazole/pharmacology*
;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
;
Sulfides
7.Subcutaneous zygomycosis due to Basidiobolus ranarum in a Filipino child responding to itraconazole: A case report
Maria Christina Corazon C. Gonzalez ; Eleanor L. Letran
Journal of the Philippine Dermatological Society 2020;29(2):78-82
Introduction: Subcutaneous zygomycosis or basidiobolomycosis is caused by a saprophytic fungi Basidiobolus ranarum (B. ranarum). It presents clinically as a slowly growing painless subcutaneous nodule more commonly on the extremity, trunk and rarely on other parts of the body. Mode of infection has not been established but most likely follows traumatic implantation. We report a gradually evolving case of basidiobolomycosis in a 12-year-old immunocompetent Filipino male with no history of trauma who responded dramatically to itraconazole.
Case summary: Subcutaneous zygomycosis is caused by Basidiobolus ranarum (B. ranarum) which is endemic in parts of Africa, India and other parts of Asia. We report an evolving case of a Filipino male child who presented with chronic and persistent subcutaneous nodules and plaques on the left extremity. Dense cell infiltrates consisting of lymphocytes, histiocytes and eosinophils were seen on histology with non-septated hyphal structures on Gomori’s methenamine silver stain. Fungal culture of the lesion yielded B. ranarum. Complete resolution of the lesions were observed after 6 months of itraconazole therapy alone.
Conclusion: This case demonstrated the gradual progression of the disease, and that the lack of a history of trauma does not exclude its diagnosis. Subcutaneous zygomycosis should be highly suspected in chronic painless subcutaneous nodules with swelling, and its early recognition is crucial to prevent progression of the disease. In patients whom an infectious cause is suspected, appropriate cultures, special staining, and sometimes repeat biopsies of new cutaneous lesions may be helpful in determining or ruling out the associated disease. Furthermore, performing PAS stain alone to identify the presence or absence of a fungi is insufficient, rather, additional staining such as GMS should be done to heighten detection of fungal elements.
Child
;
Dermatology
;
Itraconazole
;
Basidiobolus ranarum
;
entomophthoromycosis
;
Zygomycosis
8.Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.
Yusuke KOBAYASHI ; Kouji BANNO ; Haruko KUNITOMI ; Eiichiro TOMINAGA ; Daisuke AOKI
Journal of Gynecologic Oncology 2019;30(1):e10-
Ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer mortality in women. Although standard chemotherapy is the established treatment for ovarian cancer, the prognosis remains poor, and it is highly anticipated that new drugs will be developed. New drugs, such as humanized anti-vascular endothelial growth factor monoclonal antibodies and poly ADP-ribose polymerase inhibitors, are expected to improve clinical outcomes of ovarian cancer. However, long-term, costly research is required to develop such new drugs, and soaring national healthcare costs are becoming a concern worldwide. In this social context, drug repositioning, wherein existing drugs are used to develop drugs with new indications for other diseases, has recently gained attention. Because trials have already confirmed the safety in humans and the pharmacokinetics of such drugs, the development period is shorter than the conventional development of a new drug, thereby reducing costs. This review discusses the available basic experimental and clinical data on drugs used for other types of cancer for which drug repositioning is anticipated to repurpose the drug for the treatment of ovarian cancer. These include statins, which are used to treat dyslipidemia; bisphosphonate, which is used to treat osteoporosis; metformin, which is used to treat diabetes; non-steroidal anti-inflammatory drugs; ivermectin, an antiparasitic agent; and itraconazole, an anti-fungal agent. These drugs will play an important role in future drug repositioning strategies for ovarian cancer. Furthermore, drug repositioning is anticipated to extend not only to ovarian cancer treatment but also to ovarian cancer prevention.
Adenosine Diphosphate Ribose
;
Anti-Inflammatory Agents, Non-Steroidal
;
Antibodies, Monoclonal
;
Drug Repositioning*
;
Drug Therapy
;
Dyslipidemias
;
Endothelial Growth Factors
;
Female
;
Health Care Costs
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Itraconazole
;
Ivermectin
;
Metformin
;
Mortality
;
Osteoporosis
;
Ovarian Neoplasms*
;
Pharmacokinetics
;
Prognosis
9.A Case of Subcutaneous and Intranasal Phaeohyphomycosis Caused by Microsphaeropsis arundinis in an Immunocompromised Patient Misdiagnosed with Mucormycosis
Hoon CHOI ; Choong Jae KIM ; Min Sung KIM ; Bong Seok SHIN ; Chan Ho NA
Annals of Dermatology 2019;31(5):571-575
Microsphaeropsis arundinis is a dematiaceous fungus capable of causing soft tissue infections known as phaeohyphomycosis, mostly in immunocompromised individuals. These infections arise from the traumatic inoculation of fungal materials into the subcutis, and can spread to adjacent subcutaneous tissues or via the lymphatics in a sporotrichoid manner. A 76-year-old man presented with diffuse erythematous plaques and swelling on both forearms and dorsal hands, and rhinalgia. He had been undergoing treatment for hypertension, angina pectoris, and diabetes. Histopathologic examinations of the skin, painful nasal septum, and molecular identification using internal transcribed spacer regions confirmed a diagnosis of subcutaneous and intranasal phaeohyphomycosis caused by M. arundinis. The patient was treated with oral itraconazole for over 5 months, and no recurrence was observed until the time of writing this manuscript. We report a rare case of subcutaneous and intranasal phaeohyphomycosis caused by M. arundinis and propose that confirmation of the causative strains is necessary, as it could affect the prognosis and treatment of the disease.
Aged
;
Angina Pectoris
;
Diagnosis
;
Forearm
;
Fungi
;
Hand
;
Humans
;
Hypertension
;
Immunocompromised Host
;
Itraconazole
;
Mucormycosis
;
Nasal Septum
;
Phaeohyphomycosis
;
Prognosis
;
Recurrence
;
Skin
;
Soft Tissue Infections
;
Subcutaneous Tissue
;
Writing
10.Unusual Presentation of Subcutaneous Phaeohyphomycosis by Alternaria alternate
Ji Yeon LEE ; Miri HYUN ; Hyun Ah KIM ; Seong Yeol RYU
Annals of Dermatology 2019;31(5):563-566
The Alternaria species are dematiaceous fungi. Human infection due to dematiaceous fungi is uncommon. Most reported cases of alternariosis have occurred in patients with immunodeficiency. The majority of cases were solid-organ transplantation recipients. Cutaneous alternariosis lesions are usually asymptomatic solitary nodules, plaques of ulcers or subcutaneous cysts. Here we report a case of a 77-year-old female who presented with hemorrhagic skin necrosis in right arm that had developed from hemorrhagic bullae. Her prior medical history included iatrogenic Cushing's syndrome, hypertension, interstitial lung disease and congestive heart failure. Following administration of itraconazole, her lesions improved.
Aged
;
Alternaria
;
Alternariosis
;
Arm
;
Cushing Syndrome
;
Female
;
Fungi
;
Heart Failure
;
Humans
;
Hypertension
;
Itraconazole
;
Lung Diseases, Interstitial
;
Necrosis
;
Phaeohyphomycosis
;
Skin
;
Ulcer


Result Analysis
Print
Save
E-mail